TEVA PHARMACEUTICAL INDUSTRIES LTD.
History
| Year | Detail |
|---|---|
| 1901 | Teva established in Jerusalem as a small wholesale drug business by Chaim Salomon, Moshe Levin and Yitschak Elstein and is named S.L.E after its founders. |
| 1939 | During World War II, with the absence of imports, these plants are the sole source of pharmaceutical supplies for the local market and neighboring countries |
| 1951 | Teva begins trading on the Tel Aviv Stock Exchange (TASE) as the Teva Middle East Pharmaceutical Chemical Works Company Ltd. |
| 1976 | Teva, Assia, and Zori unite to create Israel’s largest drug maker - Teva Pharmaceutical Industries Ltd. Eli Hurvitz becomes first CEO of the merged company. |
| 1977 | Teva takes its first step abroad into Europe with the acquisition of Orphahell in the Netherlands. |
| 1980 | The Kfar Saba manufacturing facility is granted approval by the FDA in 1982. |
| 1984 | US Hatch-Waxman Act is passed, enabling Teva’s entry into generic medicines. |
| 1985 | Teva expands its U.S. market share through a joint venture with W.R. Grace, and the acquisition of Lemmon facilitates Teva’s entry into the U.S. market. |
| 1988 | Teva acquires Abic, the second largest pharmaceutical company in Israel, and completes the acquisition of Israeli API producer Plantex Ltd. |
| 1994 | Teva opens its flagship Teva-Tech API production facility at Ramat Hovav in Israel’s Negev desert. |
| 1996 | Acquisition of APS/Berk in the U.K. marks Teva’s first entry into a major Western European market. |
| 1996 | Teva’s innovative treatment for multiple sclerosis (MS), and the first specialty medicine for the company, is approved by the FDA. |
| 2000 | Acquisition of Novopharm Ltd., the second largest producer of generics in Canada, and its Hungarian subsidiary Human. Teva becomes the largest generic pharmaceutical company in North America. |
| 2001 | Teva’s innovative treatment for multiple sclerosis receives European Union approval. |
| 2003 | Acquisition of Regent Drugs Ltd. in India (renamed Teva API India Ltd.), which joins Teva’s API division. |
| 2004 | Acquisition of Sicor Inc. and its subsidiaries, bringing together Teva's successful oral dose generic drugs franchise with Sicor's leading generic injectable business, API and biogenerics capabilities. |
| 2005 | Teva's innovative drug for the treatment of Parkinson’s disease is approved for marketing in Israel and the EU. The treatment is later approved by the FDA in 2006. |
| 2006 | Acquisition of IVAX Corporation in the U.S. strengthens Teva’s worldwide presence through subsidiaries in Europe, Latin America and the Far East. The acquisition brings Teva a rich pipeline of generic and proprietary products in the complementary areas of respiratory, CNS, and oncology. |
| 2008 | Acquisition of Barr Pharmaceuticals in the U.S., including subsidiary PLIVA in Europe, enhances Teva’s leadership position in the US and key global markets, and strengthens Teva's portfolio and pipeline. |
| 2010 | Acquisition of Germany’s ratiopharm significantly increases Teva's market share in Europe, harnessing ratiopharm's excellent foundation for biosimilars, branded generics and tenders. |
| 2011 | Acquisition of Cephalon and its global subsidiaries strengthens Teva’s therapeutic diversification while providing a leadership position in branded and specialty pharmaceuticals |
| 2012 | Joint venture with Handok provides Teva with entrance into the South Korean pharmaceutical market and Teva begins trading on the NYSE (New York Stock Exchange). |
| 2014 | Acquisition of Labrys Biologics Inc. in the US opens the door for Teva to a strong and novel migraine prevention and treatment franchise within its CNS portfolio. |
| 2015 | Teva acquires Auspex, in order to strengthen Teva's core central nervous system franchise for treatment of movement disorders. |
| 2016 | Teva establishes a business venture with Takeda, Japan's largest pharmaceutical company leveraging Teva’s deep marketing expertise, commercial and medical excellence, with Takeda’s leading brand reputation and strong distribution presence in Japan. |
| 2016 | Teva acquires Actavis Generics, significantly expanding Teva’s generic product portfolio, R&D capabilities, product pipeline and global operational network. |
| 2016 | Teva acquires Anda Inc., a leading distributor of generic pharmaceuticals in the U.S. |
| 2021 | Teva celebrates 120 years since its founding, focused on being a global leader in generic and biopharmaceutical medicines, with a strong innovative portfolio. |
BCC Research Beacon 